Compare Crispr Therapeutics AG (CRSP) vs Ishares Msci Italy ETF (EWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ishares Msci Italy ETF — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Ishares Msci Italy ETF trades at $60.66. The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | EWI | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $61.14 |
52-Week Low | $44.34 | $47.32 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EWI trades at $60.47, down 0.2% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The stock is near key resistance at $61, with support at $60. Recent news highlights Italy's economic recovery narrative and a 52-week high, though financial ratios are currently unavailable for detailed fundamental assessment.
The outlook is cautiously optimistic given technical strength and positive European market sentiment, but risks include Italy's stagflationary conditions and energy price volatility. Investment appeal hinges on continued economic improvement and resolution of macroeconomic headwinds impacting European equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →
